Today, Haihe Biopharma (Haihe), announced that the companys self-developed selective PARP1 inhibitor (R&D code: HH10...

Haihe Biopharma Co., Ltd. (hereinafter “Haihe”) and Taiho Pharmaceutical Co., Ltd. (hereinafter “Taiho”) (“HaiHe”)...

Shanghai, China, today -Haihe Biopharma Co., Ltd. (“HaiHe”) announced that its highly selective PI3K122:553-7.